Position：Hospital President, Director of HPB Surgery
Medical School: Zhejiang University School of Medicine, China
Academic Rank: Professor of Surgery, Chief Physician
Surgery and comprehensive therapy of hepatic, pancreatic and bililary tumors
Precision surgery of complicated hepatobiliary and pancreatic diseases, including surgery for hilar cholangiocarcinoma, pancreatic cancer that requires vascular resection and reconstruction, and biliary tract tumor
Minimally invasive surgery of hepatobiliary and pancreatic tumors, and da Vinci robotic-assisted surgery
Liver transplantation, including living donor liver transplantation for adults and children, split liver transplantation, etc.
Diagnosis and treatment of other intractable or rare hepatobiliary and pancreatic diseases
State Scientific and Technological Progress Award, First Prize, 2015
State Scientific and Technological Progress Award, First Prize, 2013
Zhejiang Scientific and Technological Progress Award, First Prize, 2009
State Scientific and Technological Progress Award, Second Prize, 2008
Zhejiang Scientific and Technological Progress Award, First Prize, 2007
Zhejiang Scientific and Technological Progress Award, First Prize, 2005
Zhejiang Scientific and Technological Progress Award, Third Prize, 2001
Zhejiang Scientific and Technological Progress Award, First Prize, 2000
Vice President, Chinese Hospital Association
Standing Committee, Chinese Medical Association Surgery Group
Standing Committee, Chinese Medical Association Organ Transplantation Group
Chairman, ERAS Expert Committee of National Health Commission
Chairman, ERAS Expert Committee of Chinese Medical Doctor Association Surgery Group
Standing Committee, Chinese Medical Doctor Association Surgery Group
Vice Chairman, Robotic surgeon Committee Surgery Branch of Chinese Medical Doctor Association
Vice Chairman, Pancreatic Disease Committee of Chinese Research Hospital Association
Vice Chairman, Organ Acquisition and Distribution Management Committee of Chinese Hospital Association
Vice Chairman, China International Exchange and Promotion Association for Medical and Healthcare Surgery Group
Standing Committee, Pancreatic Disease Expert Committee of Chinese Medical Doctor Association
Vice Chairman, Organ Acquisition and Evaluation Group of Chinese Medical Association Organ Transplantation Association
Vice Chairman, China Internet Health Industry Alliance
Appointment Chairman, Zhejiang Medical Association Surgical Oncology Group
Chairman, Zhejiang Medical Association ERAS Group
Vice Chairman, Zhejiang Medical Association Surgery Group
Associate Editor-in-Chief, World Journal of Emergency Medicine
Editorial Board Member, Hepatobiliary & Pancreatic Diseases International (HBPD INT)
Editorial Board Member, Chinese Journal of Transplantation
Editorial Board Member, Chinese Journal of Pancreatology
Editorial Board Member, Chinese Journal of Critical Care Medicine
Editorial Board Member, Journal of Translational Medicine
Editorial Board Member, Narrative Medicine
First in China to systematically report on the technology of donor liver recovery and several post-operative key points for living donor liver transplantation.
Completed more than 1000 liver transplantations. Carrying out the first cases of Ex Situ Hepatectomy and Liver Autotransplantation as well as the minimally invasive acquisition living donor liver transplantation for children in Zhejiang Province. First to perform child living donor liver transplantation, split liver transplantation and living donor liver transplantation for amino acid metabolism disease in SAHZU, with a 100% survival rate of recipient children, which is leading the world.
Devoted to research and development of AI-assisted diagnosis system for liver cancer whose accuracy of liver segmentation recognition, liver cancer localization and diagnosis rank first in the world.
Having developed a variety of nanomedicines for the treatment of hepatobiliary and pancreatic diseases and the results have been published in authoritative journals such as Adv Sci and Theranostics, etc.
Yuan Ding, Hao Xu, Chang Xu, Zongrui Tong, Sitong Zhang, Yang Bai, Yining Chen, Qianhui Xu, Liuzhi Zhou, Hao Ding, Zhongquan Sun, Sheng Yan*, Zhengwei Mao*, Weilin Wang*. A Nanomedicine Fabricated from Gold Nanoparticles Decorated Metal Organic Framework for Cascade Chemo/Chemodynamic Cancer Therapy. ADVANCED SCIENCE, 2020.6.
Yuan Ding, Zhongquan Sun, Zongrui Tong, Sitong Zhang, Jie Min, Qianhui Xu, LiuzhiZhou, Huang Yang, Haibing Xia*, Zhengwei Mao*, Weilin Wang*. Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy. THERANOSTICS, 2020.4, 10(12), 5195-5208.
Yang Yang, Yuan Ding, Bo Fan, Yi Wang, Zhengwei Mao*, Weilin Wang*, Jindan Wu*. Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis. JOURNAL OF CONTROLLED RELEASE, 2020.2, 321, 463-474.
Linshi Zhang, Jiarong Zhou, Yingcai Yan, Xiaohu Zhou, Quan Zhou, Rong Du, Shiqi Hu, Wenhao Ge, Yu Huang, Hao Xu, Yang Kong, Huilin Zheng, Yuan Ding, Youqing Shen*, Weilin Wang*. Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts. CANCER LETTERS, 2019.8, 465, 36-44.
Yi Zheng, Xiaoxuan Tu, Peng Zhao, Weiqin Jiang, Lulu Liu, Zhou Tong, Hangyu Zhang, Cong Yan, Weijia Fang, WeilinWang. ARandomised Phase II Study of Second-Line XELIRI Regimen Versus Irinotecan Monotherapy in Advanced Biliary Tract Cancer Patients Progressed on Gemcitabine and Cisplatin.British Journal of Cancer,2018;119: 291-295.
Yang Kong, Lufei Zhang, Yu Huang, Tianyu He, Linshi Zhang, Xinyi Zhao,Xiaohu Zhou, Dongkai Zhou, Yingcai Yan, Jiarong Zhou, Haiyang Xie, Lin Zhou,Shusen Zheng*, Weilin Wang*. Pseudogene PDIA3P1 promotes cell proliferation,migration and invasion, and suppresses apoptosis in hepatocellular carcinoma byregulating the p53 pathway, Cancer Letters, 2017, 407: 76-83.
Linghui Chen, Qiang Sun, Dongkai Zhou, Wei Song, QifanYang,BingjieJu, Lufei Zhang, Haiyang Xie, Lin Zhou, Zhenhua Hu, HangpingYao,Shusen Zheng*, Weilin Wang*. HINT2 triggers mitochondrial Ca influx by regulating themitochondrial Ca uniporter (MCU) complex and enhances gemcitabine apoptoticeffect in pancreatic cancer, Cancer Letters, 2017, 411: 106-116.
Sinan Lu, Yuan Zhang, Xiaohu Zhou, Dongkai Zhou, Qifan Yang, Bingjie Ju, Xinyi Zhao, Zhenhua Hu, Haiyang Xie, Lin Zhou, Shusen Zheng & Weilin Wang.Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis. Sci Rep, 2016. 6: p. 36944.
Y Yan, M Xie, L Zhang, X Zhou, H Xie, Z Lin, S Zheng, W Wang. Ras-related associated with diabetes gene acts as a suppressor and inhibits Warburg effect in hepatocellular carcinoma. Onco Targets Ther, 2016. 9: p. 3925-37.
D Chen, Q Sun, X Cheng, L Zhang, W Song, D Zhou, J Lin, W Wang. Genome-wide analysis of long noncoding RNA (lncRNA) expression in colorectal cancer tissues from patients with liver metastasis. Cancer Med, 2016. 5(7): p. 1629-39.
Zhou X, Zhang L, Yang Y, Zhang Y, Xie H, Zheng S, Wang W. MicroRNA-761 is upregulated in hepatocellular carcinoma and regulates tumorigenesis by targeting Mitofusin-2. Cancer Sci, 2016. 107(4): p. 424-32.
Wang, W., et al., Mitofusin-2 triggers mitochondria Ca2+ influx from the endoplasmic reticulum to induce apoptosis in hepatocellular carcinoma cells. Cancer Lett, 2015. 358(1): p. 47-58.
Wang, W., et al., Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci, 2013. 104(11): p. 1523-31.
The role and pathogenesis of receptor tyrosine kinase RON in invasive metastasis of pancreatic cancer cells. Funding Source: National Natural Science Foundation of China.
Innovative research on precision hepatectomy technology assisted by artificial intelligence vision system. Funding Source: Key R&D Project of Zhejiang Province.
Research on precision diagnosis and treatment of pancreatic cancer. Funding Source: Province-Ministry Cooperative Major Medicine and Health Project of Zhejiang Province.
Novel mechanisms of acquired resistance by hypoxic pancreatic cancer cells towards specific tyrosine kinase inhibitors. Funding Source: National Natural Science Foundation of China.
Establishment and application of early warning technology for pancreatic cancer based on trace DNA detection. Funding Source: Science and Technology Major Project of Zhejiang.
Key technology research and equipment development and verification of medical IoT for digital hospitals. Funding Source: National Science and Technology Major Project.
Research on the correlation between organ transplantation infection and intestinal microecology. Funding Source: 973 Program.
Translational medicine research on early diagnosis and comprehensive therapy of pancreatic cancer. Funding Source: Special Research Project for Public Health Industry.
The mechanism of HSG induce cell apoptosis and inhibit proliferation of hepatocellular carcinoma. Funding Source: National Natural Science Foundation of China.
The mechanism of HSG induce cell apoptosis of pancreatic cancer, Scientific Research Fund of National Health Commission.
Research on early warning and individualized comprehensive therapy technology system for liver cancer, Science and Technology Major Project of Zhejiang Province.
Research on comprehensive therapy technology system of pancreatic cancer, Major Project Supported by the 11th Five-Year Plan.
Prevention of liver graft chronic rejection using the technique of HSG gene transduction, National Natural Science Foundation of China.
Experimental research of HSG gene transfection to prevent chronic rejection of liver transplantation, Province-Ministry Cooperative Project.